Article Details
Retrieved on: 2024-10-14 21:21:09
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses RedHill Biopharma's contract with BARDA to develop opaganib, a novel treatment for Ebolavirus, highlighting its mutation-resistant properties and situating it within the biopharma landscape of Ebola interventions like monoclonal antibodies.
Article found on: www.precisionvaccinations.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here